On Apr. 27, 2020, Neurocrine Biosciences announced the FDA approved once-daily oral ONGENTYS (opicapone) 25 mg and 50 mg capsules as an add-on treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing ﾓoffﾔ episodes. ONGENTYS also increases ﾓonﾔ time without troublesome dyskinesia, the time when the motor symptoms of a patient with Parkinsonﾒs disease are better controlled.